#None #SOPHiA GENETICS #MSK-ACCESS #AI oncology

SOPHiA GENETICS Reports Second Quarter 2025 Results

On August 5, 2025, SOPHiA GENETICS (Nasdaq: SOPH), a prominent cloud-native software company at the forefront of data-driven medicine, unveiled its financial results for the second quarter ending June 30, 2025. The report indicated a strong performance driven by increased demand for its innovative medical applications and cloud-based technologies.

Financial Overview

During the second quarter, SOPHiA GENETICS achieved revenues of $18.3 million, reflecting a 16% increase compared to the same period in the previous year. The company’s gross margin was reported at 67.0% on a standard basis, while an adjusted gross margin reached 74.4%, which is noteworthy compared to 68.2% and 73.2% respectively from the previous year’s numbers. Despite the impressive increases in revenue, the company recorded a net loss of $22.4 million, marking a 48% rise compared to the prior year, largely influenced by foreign exchange impacts.

Strategic Advances

Jurgi Camblong, Ph.D., CEO and Co-founder, expressed confidence in the quarterly growth attributed to various initiatives. This includes the transformative applications like MSK-ACCESS®, which are gaining traction across geographies. Even with rising operational costs, SOPHiA GENETICS successfully improved its cash burn to $8.7 million, a 35% enhancement year-over-year.

A significant achievement highlighted in the report is the 35 new core genomics customers acquired in Q2, which capitalizes on the surging clinical demand. Notably, SOPHiA GENETICS also secured the largest contract in its history, a multi-year AI-driven partnership with AstraZeneca aimed at enhancing breast cancer treatment outcomes.

Business Highlights

Some key performance indicators for Q2 2025 include:

• - 95,000 analyses performed on the SOPHiA DDMTM platform, signifying a 9% year-over-year volume growth.
• - Increased core genomics customers now stands at 490, up from 457 in Q2 2024.
• - Noteworthy adoption of innovative applications like MSK-ACCESS®, with several leading hospitals in different countries signing on, including institutions from Riyadh, Barcelona, Padua, Mumbai, and Sydney.

The expansion of partnerships, especially with Dasa, Latin America's largest medical diagnostics provider, reflects SOPHiA's commitment to bringing advanced medical applications to diverse markets, further bolstering its presence.

Growth Outlook

For the remainder of 2025, SOPHiA GENETICS reaffirmed its financial outlook anticipating total revenue between $72 million and $76 million, with an adjusted EBITDA loss between $35 million and $39 million. Camblong indicated a path towards breakeven adjusted EBITDA by late 2026, with profitability expected in the second half of 2027.

The approach emphasizes optimizing compute costs through the platform's data processing capabilities while expanding the feature set to cater to broader clinical and biopharmaceutical needs. The strong emphasis on operational excellence has fortified the company’s capital position, which endures with a cash reserve of $94.8 million as of the report’s close.

Conclusion

SOPHiA GENETICS is steadily progressing towards its goal of enhancing healthcare quality worldwide through data-driven insights and AI technology. With robust growth indicators, strategic collaborations, and a sustainable financial forecast, the company is poised for significant developments in the medical landscape, especially in oncology and rare disease diagnostics. For more information about SOPHiA GENETICS and their ongoing efforts, visit SOPHiA GENETICS’ official website.